Evaxion Licenses Vaccine Candidate EVX-B3 to MSD
Evaxion A/S, a clinical-stage TechBio company known for its AI-Immunology™ powered vaccines, has secured a significant partnership with MSD (Merck & Co., Inc.). The deal marks a pivotal step for Evaxion as MSD exercises its option to license the vaccine candidate EVX-B3, receiving a cash injection of $7.5 million. This capital will extend Evaxion's financial runway into 2027 and enhance its capacity to foster innovative developments.
Key Financial Aspects of the Licensing Agreement
Under the terms of this agreement, Evaxion is set to benefit from further developmental, regulatory, and sales milestone payments that could total up to $592 million. This also includes potential royalties on the net sales of the vaccine. MSD will take charge of all expenses related to the advancement of EVX-B3, allowing Evaxion to focus on its proprietary AI-Immunology™ research and further projects in its pipeline.
EVX-B3: A Vaccine for Unmet Medical Needs
Currently in preclinical development, EVX-B3 targets a pathogen linked to repeated infections with serious complications and for which existing vaccines are lacking. Utilizing Evaxion's AI-Immunology™ platform, the vaccine exemplifies their capability to discover new vaccine targets that might otherwise remain unaddressed.
Excitement Surrounding the Collaboration
Birgitte Rønø, the Chief Scientific Officer and interim CEO of Evaxion, expressed enthusiasm about this collaboration, noting that it is not just a financial win but also a strong endorsement of their technology. The collaboration with MSD, a leader in the vaccine market, indicates a robust validation of Evaxion's AI-driven approach. This partnership represents a significant step towards realizing the full potential of their AI-discovered vaccine candidate.
MSD's Perspective on the New Partnership
Tarit Mukhopadhyay, Vice President and Head of Infectious Diseases and Vaccine Discovery at MSD, shared their excitement about further evaluating the potential of EVX-B3. They aim to integrate this vaccine candidate into their early vaccine pipeline, exploring the unique targets identified by Evaxion’s AI-Immunology™ framework.
Future Outlook and Business Strategy
The partnership not only strengthens Evaxion's financial position but also demonstrates its strategy to pursue impactful collaborations that can amplify its research capabilities. The $7.5 million cash influx will be strategically allocated to advancing their R&D projects and enhancing their AI-Immunology™ platform.
Upcoming Developments with EVX-B2
Alongside the EVX-B3 advancement, Evaxion and MSD will also extend the evaluation period for a second vaccine candidate, EVX-B2, which is aimed at combating Gonorrhea. This vaccine was originally developed under the collaboration established in 2023. A decision about its potential licensing is anticipated in the first half of 2026.
Potential Value of EVX-B2
If MSD opts to license EVX-B2, Evaxion could receive an additional $2.5 million upfront, plus similar milestone payments and royalties as those associated with EVX-B3. This could significantly boost the company's portfolio and partnerships.
Conference and Stakeholder Engagement
Evaxion’s executive team will host a conference call and webcast to discuss these pivotal developments, allowing stakeholders to engage and ask questions live. This wave of communication reflects Evaxion's commitment to transparency and active stakeholder involvement in its ongoing projects.
Contact Information for More Inquiries
For further details about the partnership and upcoming projects, interested parties are encouraged to reach out to:
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
Phone: +45 53 54 82 96
Email: mak@evaxion.ai
About Evaxion A/S
Evaxion is at the forefront of utilizing artificial intelligence in immunology to develop innovative treatments aimed at cancer and infectious diseases. Their AI-Immunology™ platform harnesses the power of advanced algorithms to decode immune responses, supporting the creation of personalized vaccines. Evaxion is committed to transforming healthcare and addressing unmet medical needs through cutting-edge biotechnology.
Frequently Asked Questions
What is the partnership between Evaxion and MSD about?
The partnership involves MSD licensing the EVX-B3 vaccine candidate from Evaxion, securing a cash payment and future milestone payments for further development.
What financial benefits does Evaxion gain from this deal?
Evaxion will receive $7.5 million upfront, with potential milestone payments of up to $592 million and royalties on net sales of the EVX-B3 vaccine.
What is EVX-B3 targeting?
EVX-B3 targets a pathogen linked to recurrent infections that have serious consequences and currently lack existing vaccines.
When can we expect updates on EVX-B2?
Decisions on the licensing of EVX-B2 are anticipated in the first half of 2026 as part of the ongoing collaboration with MSD.
How can investors learn more about the developments?
Investors can participate in the upcoming conference call and webcast hosted by Evaxion to discuss recent developments and ask questions directly to the management team.
